Nanoworx Milestones: New Infrastructure and First Commercial Projects

News February 11, 2026

How can we better harness the potential of nanomedicine? Nanoworx, one of the projects funded under PharmaNL’s Shared Development Infrastructure program, was established as a new Contract Research Organisation (CRO) to automate and accelerate the development of innovative nanomedicines. With support from PharmaNL and TU/e, Nanoworx is building a sustainable infrastructure to create nanomedicine libraries and select the most promising formulations through advanced screening techniques. This approach makes nanotechnology more accessible to both academic and industrial partners and accelerates the path to clinical application.

Nanoworx Milestones
2025 was a landmark year. In just one year, Nanoworx grew from a small start-up team to a fully operational organization with a state-of-the-art laboratory for screening, optimizing, and analyzing a wide range of nanomedicine platforms. The team doubled in size, including the addition of two industrial PhD researchers. The company also expanded into multiple office spaces and completed its first commercial projects.

Another key achievement was the validation of four nanoparticle platforms, one of which was successfully applied in a commercial project with Trained Therapeutix Discovery. These results demonstrate the value of Nanoworx’s approach, which combines high-throughput screening, advanced data analysis, and robust data management systems.

With the launch of a new website and a rapidly growing network of partners, including TU/e, Pivot Park Screening Centre, and Trained Therapeutix Discovery, Nanoworx has established a solid foundation for further scale-up. The goal is to continue growing independently after the PharmaNL funding period and eventually develop into an internationally operating CDMO.

Read more on the Nanoworx website.